The antiherpesvirus activity of H2G [(R)-9-[4-hydroxy- 2(hydroxymethyl)butyl]guanine] is markedly enhanced by the novel immunosuppressive agent mycophenolate mofetil

Antimicrobial Agents and Chemotherapy

Volumn 42, Issue 12, 1998, Pages 3285-3289

  Neyts, Johan ^a   Andrei, Graciela ^a   De Clercq, Erik ^a  

^a REGA INSTITUTE FOR MEDICAL RESEARCH   (Belgium)

Author keywords

[No Author keywords available]

Indexed keywords

9 [4 HYDROXY 2 (HYDROXYMETHYL)BUTYL]GUANINE; ACICLOVIR; GANCICLOVIR; IMMUNOSUPPRESSIVE AGENT; MYCOPHENOLIC ACID 2 MORPHOLINOETHYL ESTER; PENCICLOVIR;

ANIMAL CELL; ANTIVIRAL ACTIVITY; ARTICLE; DRUG POTENTIATION; HERPES; HERPES VIRUS; HUMAN; HUMAN CELL; IMMUNOSUPPRESSIVE TREATMENT; KIDNEY GRAFT REJECTION; KIDNEY TRANSPLANTATION; NONHUMAN; PRIORITY JOURNAL; VIRUS REPLICATION;

EID: 0031758701     PISSN: 00664804     EISSN: None     Source Type: Journal    
DOI: 10.1128/aac.42.12.3285     Document Type: Article

References (26)

1. Abele, G., S. Cox, S. Bergman, B. Lindborg, A. Vissgarden, A. Karlström, J. Harmenberg, and B. Wahren. 1991. Antiviral activity against VZV and HSV type 1 and type 2 of the (+) and (-) enantiomers of (R,S)-9-[4-hydroxy-2-(hydroxymethyl)butyl]guanine, in comparison to other closely related acyclic nucleosides. Antivir. Chem. Chemother. 2:163-169.
2. Abele, G., B. Eriksson, J. Harmenberg, and B. Wahren. 1988. Inhibition of varicella-zoster virus-induced DNA polymerase by a new guanosine analog, 9-[4-hydroxy-2-(hydroxymethyl)butyl]guanine triphosphate. Antimicrob. Agents Chemother. 32:1137-1142.
3. Abele, G., A. Karlström, J. Harmenberg, S. Shigeta, A. Larsson, B. Lindborg, and B. Wahren. 1987. Inhibiting effect of (R,S)-9-[4-hydroxymethyl)butyl] guanine on varicella-zoster virus replication in cell culture. Antimicrob. Agents Chemother. 31:76-80.
4. Åkesson-Johansson, A., J. Harmenberg, B. Wahren, and A. Linde. 1990. Inhibition of human herpesvirus 6 replication by 9-[4-hydroxy-2-(hydroxymethyl)butyl]guanine (2HM-HBG) and other antiviral compounds. Antimicrob. Agents Chemother. 34:2417-2419.
5. Balzarini, J., and E. De Clercq. 1990. 9-β-D-Arabinofuranosyladenine 5′-monophosphate (araAMP) is converted directly to its antivirally active 5′-triphosphate form by 5-phosphoribosyl-1-pyrophosphate (PRPP) synthetase. Biochem. Biophys. Res. Commun. 173:781-787.
6. Balzarini, J., and E. De Clercq. 1992. Assay method for monitoring the inhibitory effects of antimetabolites on the activity of inosinate dehydrogenase in intact human CEM lymphocyte cells. Biochem. J. 287:785-790.
7. Balzarini, J., L. Naesens, M. J. Robins, and E. De Clercq. 1990. Potentiating effect of ribavirin on the in vitro and in vivo anti-retrovirus activities of 2′,3′-dideoxyinosine and 2′,3′-dideoxy-2,6-diaminopurine riboside. J. Acquired Immune Dene. Syndr. 3:1140-1147.
8. Balzarini, J., C.-K. Lee, D. Schols, and E. De Clercq. 1991. 1-β-D-Ribofuranosyl-1,2,4-triazole-3-carboxamide (ribavirin) and 5-ethynyl-1-β-D-ribofuranosylimidazole-4-carboxamide (EICAR) markedly potentiate the inhibitory effect of 2′,3′-dideoxyinosine on human immunodeficiency virus in peripheral blood lymphocytes. Biochem. Biophys. Res. Commun. 178:563-569.
9. Balzarini, J., C.-K. Lee, P. Herdewijn, and E. De Clercq. 1991. Mechanism of the potentiating effect of ribavirin on the activity of 2′,3′-dideoxyinosine (ddIno) against human immunodeficiency virus (HIV). J. Biol. Chem. 266: 21509-21514.
10. Bullingham, R., S. Monroe, A. Nicholls, and M. Hale. 1996. Pharmacokinetics and bioavailability of mycophenolate mofetil in healthy subjects after single-dose oral and intravenous administration. J. Clin. Pharmacol. 36:315-324.
11. De Clercq, E. 1995. Trends in the development of new antiviral agents for the chemotherapy of infections caused by herpesviruses and retroviruses. Rev. Med. Virol. 5:149-164.
12. De Clercq, E., J. Descamps, G. Verhelst, R. T. Walker, A. S. Jones, P. F. Torrence, and D. Shugar. 1980. Comparative efficacy of different antiherpes drugs against different strains of herpes simplex virus. J. Infect. Dis. 141: 563-574.
13. Fulton, B., and A. Markham. 1996. Mycophenolate mofetil. A review of its pharmacodynamic and pharmacokinetic properties and clinical efficacy in renal transplantation. Drugs 51:278-298.
14. Hartman, N. R., G. S. Ahluwalia, D. A. Cooney, H. Mitsuya, S. Kageyama, A. Fridland, S. Broder, and D. G. D. A. Johns. 1991. Inhibitors of IMP dehydrogenase stimulate the phosphorylation of the anti-human immunodeficiency virus nucleosides 2′,3′-dideoxyadenosine and 2′,3′-dideoxyinosine. Mol. Pharmacol. 40:118-124.
15. Keller, P. M., S. A. McKee, and J. A. Fyfe. 1985. Cytoplasmic 5′-nucleotidase catalyzes acyclovir phosphorylation. J. Biol. Chem. 260:8664-8667.
16. Lowe, D. M., W. K. Alderton, M. R. Ellis, V. Parmar, W. H. Miller, G. B. Roberts, J. A. Fyfe, R. Gaillard, P. Ertl, W. Snowden, and E. Littler. 1995. Mode of action of (R)-9-[4-hydroxy-2-(hydroxyrnethyl)butyl]guanine against herpesviruses. Antimicrob. Agents Chemother. 39:1802-1808.
17. Neyts, J., and E. De Clercq. 1997. Antiviral drug susceptibility of human herpesvirus 8. Antimicrob. Agents Chemother. 41:2754-2756.
18. Neyts, J., G. Andrei, and E. De Clercq. 1998. The novel immunosuppressive agent mycophenolate mofetil markedly potentiates the antiherpes virus activities of acyclovir, ganciclovir, and penciclovir in vitro and in vivo. Antimicrob. Agents Chemother. 42:216-222.
19. Nimmesgern, E., T. Fox, M. A. Fleming, and J. A. Thomson. 1996. Conformational changes and stabilization of inosine 5′-monophosphate dehydrogenase associated with ligand binding and inhibition by mycophenolic acid. J. Biol. Chem. 271:19421-19427.
20. Patterson, J. L., and R. Fernandez-Larsson. 1990. Molecular mechanism of ribavirin. Rev. Infect. Dis. 12:1139-1146.
21. Ransom, J. T. 1995. Mechanism of action of mycophenolate mofetil. Ther. Drug Monit. 17:681-684.
22. Shiraki, K., M. Ishibashi, T. Okuno, J. Namazue, K. Yamanishi, T. Sonoda, and M. Takahashi. 1991. Immunosuppressive dose of azathioprine inhibits replication of human cytomegalovirus in vitro. Arch. Virol. 117:165-171.
23. Sintchak, M. D., M. A. Fleming, O. Futer, S. A. Raybuck, S. P. Chambers, P. R. Caron, M. A. Murcko, and K. P. Wilson. 1996. Structure and mechanism of inosine monophosphate dehydrogenase in complex with the immunosuppressant mycophenolic acid. Cell 85:921-930.
24. Soike, K., R. Bohm, J.-L. Huang, and B. Öberg. 1993. Efficacy ot (-)-9-[4-hydroxy-2-(hydroxymethyl)butyl]guanine in African green monkeys infected with simian varicella virus. Antimicrob. Agents Chemother. 37:1370-1372.
25. Suthanthiran, M., R. E. Morris, and T. B. Strum. 1996. Immunosuppressants: cellular and molecular mechanism of action. Am. J. Kidney Dis. 28-159-172.
26. Willis, R. C., D. A. Carson, and J. E. Seegmiller. 1978. Adenosine kinase initiates the major route of rihavirin activation in a cultured human cell line. Proc. Natl. Acad. Sci. USA 75:3042-3044.